12 results about "GABAergic neuron" patented technology

A method and system for differentiating acute and chronic pain based on the functional state of specific neural circuits is proposed. This method utilizes in vivo two-photon / endoscopic calcium imaging and ex vivo brain slice patch-clamp techniques to longitudinally monitor the activity dynamics of neurons in the DRN and ZI brain regions during the acute and chronic phases of a neuropathic pain model. By extracting and analyzing calcium and electrophysiological signal parameter sets, distinguishing criteria are established: if the activity of 5-HTergic neurons in the DRN is specifically enhanced in the acute phase, the indication is acute pain; if the activity of GABAergic neurons in the ZI is specifically enhanced in the chronic phase, the indication is chronic pain. This invention achieves an objective and precise differentiation of the transition from acute to chronic pain at the level of specific neural circuits, providing a new strategy and tool for pain mechanism research and clinical diagnosis and treatment.

The present invention provides novel irisin peptides (e.g, irisin glycosylation mutants and biologically active fragments thereof). Also provided are methods for preventing or reducing degeneration of dopaminergic neurons and / or preventing or ameliorating at least one motor deficit in a subject in need thereof, such as in a subject with α-synucleinopathy, using the novel irisin peptides to modulate irisin-induced integrin signaling. The novel irisin peptides can also be used in methods for increasing expression of brain-derived neurotrophic factor (BDNF), and / or treating or preventing neurological diseases or disorders that would benefit from decreased neuronal cell death and / or increased neuronal survival in a subject. In addition, the novel irisin peptides may be used in methods for preventing or treating muscular atrophy or muscular dystrophy.

A cell population comprising Corin- and / or Lrtm1-positive cells was produced by the following steps (1) and (2), from which Corin positive and / or Lrtm1 positive cells are collected using a substance that binds to Corin and / or a substance that binds to Lrtm1, and dopaminergic neuron progenitor cells are produced by performing suspension culture of the Corin positive and / or Lrtm1 positive cells in a culture solution containing one or more nutritional factors:(1) a step of performing adhesion culture of pluripotent stem cells in a medium for maintaining undifferentiated state containing a Sonic hedgehog (SHH) signal stimulant, and an undifferentiated state-maintaining factor in the absence of feeder cells but in the presence of an extracellular matrix, and(2) a step of culturing the cell population obtained in the step (1) in a culture solution containing one or more differentiation-inducing factors.

This invention discloses the application of bimatoprost in the preparation of drugs for the prevention and / or treatment of Parkinson's disease, within the field of drug reuse. Bimatoprost is a prostaglandin F2α analog, currently mainly used for glaucoma and eyelash growth. This invention has found that bimatoprost can improve Parkinson's disease-related behavioral disorders, increase the expression of tyrosine hydroxylase, a protein associated with dopaminergic neurons in the substantia nigra, and reduce the abnormal accumulation of α-synuclein, thus exhibiting good ameliorative and protective effects against Parkinson's disease. This invention provides a new drug option for the treatment of Parkinson's disease.

The application discloses application of anterior piriform cortex GABAergic neurons as an analgesic target point, and relates to the technical field of neuroscience and pain. GABA The application discloses that the neural loop (APC GABA →MD) from the anterior piriform cortex GABAergic neurons to the thalamic dorsal medial nucleus plays a key role in pain regulation. Experiments prove that the loop can not only relieve acute pain, but also has a significant analgesic effect on the clinical treatment of intractable chronic inflammatory pain and neuropathic pain models, and shows a wide treatment application prospect.

Artificial expression constructs for modulating gene expression in targeted central nervous system cell types are described. The artificial expression constructs can be used to express synthetic genes or modify gene expression in forebrain glutamatergic neurons.

Methods for electrical modulation of inflammation or serum TNF levels in a subject.

The application belongs to the technical field of biological medicine, and discloses application of PPIA in preparation of a medicine for preventing or treating Parkinson's disease, wherein an amino acid sequence of the PPIA is shown as SEQ ID NO. 5. The application proves for the first time that PPIA expression is significantly up-regulated in Parkinson's disease cells and mouse models; by inhibiting the expression or activity of PPIA, the damage of dopaminergic neurons in the Parkinson's disease model can be significantly reduced, and the motor dysfunction of the model mice can be improved. Meanwhile, the application also finds for the first time that paederoside can significantly inhibit the expression of PPIA, and is a new specific inhibitor of PPIA. The application determines that PPIA is a brand-new drug target for preventing and treating Parkinson's disease, and can be used for screening and discovering medicines for preventing and treating Parkinson's disease, and can inhibit the death of dopaminergic neurons by inhibiting the expression of PPIA, thereby providing a new direction and theoretical basis for the research and development of medicines for preventing or treating Parkinson's disease and clinical treatment.

The application discloses a Parkinson's disease cell model with mitochondrial damage, a construction method and application thereof. The construction method utilizes a target virus containing a CRISPR / Cas9 system to infect dopaminergic neuron cells, can precisely knock out a gene fragment coding mitochondrial transcription factor A in a nucleus gene of the dopaminergic neuron cells, makes the dopaminergic neuron cells reduce expression of TFAM protein, causes mitochondrial dysfunction, and further forms the Parkinson's disease cell model with mitochondrial damage. The mitochondrial damage feature of the Parkinson's disease cell model provided by the application is hereditary, therefore, after CRISPR / Cas9 gene editing is performed on primary cells, the edited primary cells are cultured to obtain a sufficient number of cell models for subsequent experiments and research. Compared with a method of exposing to rotenone, the method does not need to re-model each time the Parkinson's disease cell model is used, and the subcultured cells can be directly taken.

The application discloses an olfactory training system for activating a motor-olfactory-hippocampal neural network and application, the system comprises a plurality of different odor sources, the odor source is used for alternating olfactory stimulation to stroke patients, so as to improve the cognitive function and / or olfactory function of the patient. The application firstly discloses that the function connection of the motor-olfactory-cognitive brain area is disordered after stroke, the function of the VIP neuron of the motor cortex (MO) around the infarction is inhibited; the VIP neuron of the MO region dominates the GABA neuron of the dorsal peripeduncular area (DP) through an inhibitory pathway, activating the pathway can remove the inhibition of the glutamatergic pyramidal neuron of the DP, enhance the excitatory input to the hippocampal CA3 region, and restore the olfaction and spatial memory. The application proves that the structured olfactory training can activate the loop, and significantly improve the cognitive function of the stroke patient. The application provides a simple and non-invasive stroke rehabilitation strategy.

This invention provides a plant-derived bioactive polypeptide and its use in the prevention or treatment of Parkinson's syndrome, belonging to the field of polypeptide bioengineering technology. The amino acid sequence of the bioactive polypeptide is MKGASSIMYALG, and it is prepared from Fuding white tea raw materials through a directed two-step enzymatic hydrolysis process. This polypeptide can significantly alleviate 6-OHDA-induced damage to dopaminergic neurons in BZ555 nematodes and significantly improve motor dysfunction in Parkinson's syndrome model animals. Simultaneously, it can downregulate the expression levels of pro-inflammatory factors such as IL-1β and IL-18 in the serum of model mice, upregulate dopamine content in the substantia nigra region of brain tissue in model rats, and reduce monoamine oxidase B activity. These results indicate that the Fuding white tea-derived bioactive polypeptide of this invention has definite preventive and therapeutic effects on Parkinson's syndrome, and has significant development value and broad application prospects in the pharmaceutical field.

Disclosed is a composition containing 2′-FL for ameliorating, preventing or treating diseases caused by reduction of dopamine. 2′-FL has an advantage of effectively preventing or treating diseases caused by a decrease in dopamine by effectively suppressing degeneration of dopaminergic neurons. In particular, the composition of the present invention is effective in preventing, treating, or ameliorating Parkinson's disease caused by reduction of dopamine because it contains 2′-fucosyllactose (2′-FL) as an active ingredient, thereby suppressing the decrease in dopaminergic neurons and exhibiting an effect of improving motor activity.